News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca Sees First Merck & Co., Inc. Payment Capped At $3.3 Billion
March 14, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, March 14 (Reuters) - AstraZeneca Plc said on Tuesday it believed the first option payment due to Merck & Co Inc in 2008 under a complex marketing partnership scheme between the firms was unlikely to exceed a net $3.3 billion.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
AstraZeneca Pharmaceuticals LP
Merck & Co.
MORE ON THIS TOPIC
Funding
Novo Foundation Pumps $850M Into Denmark, Europe to Bolster Innovation
January 16, 2026
·
2 min read
·
Tristan Manalac
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
January 16, 2026
·
3 min read
·
Dan Samorodnitsky
Drug pricing
Trump Takes Drug Pricing Fight To Insurers With ‘The Great Healthcare Plan’
January 15, 2026
·
2 min read
·
Annalee Armstrong
Legal
Compounder Sues Lilly, Novo, Claims Coordinated Crackdown
January 15, 2026
·
2 min read
·
Tristan Manalac